NASDAQ:PULM Pulmatrix Q3 2024 Earnings Report $1.41 +0.01 (+0.71%) Closing price 04:00 PM EasternExtended Trading$1.40 -0.01 (-0.71%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pulmatrix EPS ResultsActual EPS-$0.71Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APulmatrix Revenue ResultsActual Revenue$0.37 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APulmatrix Announcement DetailsQuarterQ3 2024Date11/8/2024TimeBefore Market OpensConference Call DateFriday, November 8, 2024Conference Call Time7:00AM ETUpcoming EarningsPulmatrix's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly Report(10-Q) Pulmatrix Earnings HeadlinesPulmatrix Inc.: Pulmatrix Announces First Quarter 2026 Financial ResultsMay 15, 2026 | finanznachrichten.dePulmatrix Inc : PULMMay 15, 2026 | 247wallst.comThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.June 15 at 1:00 AM | American Alternative (Ad)Pulmatrix Announces First Quarter 2026 Financial ResultsMay 15, 2026 | prnewswire.comPulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned MergerApril 21, 2026 | prnewswire.comPULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its ShareholdersApril 13, 2026 | businesswire.comSee More Pulmatrix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email. Email Address About PulmatrixPulmatrix (NASDAQ:PULM) is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches. Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA). Another key candidate, PLX100, is being investigated for pulmonary sarcoidosis, a chronic inflammatory disease of the lungs. Both programs have progressed through preclinical and early clinical stages, demonstrating favorable tolerability profiles and the potential to reduce systemic side effects. Founded in 2005 and headquartered in Lexington, Massachusetts, Pulmatrix combines formulation science with pulmonary pharmacology to advance its pipeline. The company collaborates with leading academic institutions and clinical research centers across the United States to conduct studies in diverse patient populations, leveraging its R&D infrastructure to support efficient development pathways. Pulmatrix’s leadership team brings extensive experience in respiratory drug development and regulatory strategy. Focused on advancing its inhaled therapies through pivotal trials and strategic partnerships, the company aims to expand its portfolio into additional acute and chronic respiratory conditions, ultimately improving patient outcomes and quality of life.View Pulmatrix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big QuestionAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationForget AI for a Moment, This Homebuilder Is Stealing the Show Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
